During the weekend, Sprint Bioscience announced that the US firm Day One has decided to discontinue ...
Redeye returns with a more in-depth take on the Q1 report.
Digging into the feasibility study and mineral resource update Feasibility study arrives an NPV of S...
Redeye provides a research update following the Q1 report recently published by Initiator Pharma.
Redeye provides a research update following Catella’s Q1 2025 report.
Redeye returns with positive estimate adjustments following I-Tech's Q1 2025 report that delivered s...
Q1e: top line and adj. EBITDA +14% and 9% y-o-y '25e-'27e sales down 3%, limited adj.
Redeye provides a brief comment on the news that 85% of the TO 12 warrant program has been secured a...
- Investments in sales held back margins in Q1... - .
Kinda Brave Entertainment Group AB (”Kinda Brave” eller ”Koncernen”) har publicerat Koncernens delår...
Fastighetsbolaget Trianon har inlett 2025 med en miljardförsäljning av fastigheter till storägaren B...
Redeye is optimistic about Alligator’s completion of GMP production of mitazalimab, a precondition f...
Redeye notes an exceptionally strong Q1 with record sales.
Redeye provides an initial comment on Catella’s Q1 2025 report.
Redeye updates its view on Xbrane following a stronger-than-expected Q1 report, with both revenue an...
Redeye updates on W5 Solutions following a softer than expected Q1-report.
Sales 9% below us, but partly temporary; orders grew 61% Mixed outlook, reiterates guidance, but cit...
Redeye updates its estimates after reviewing Tessin's Q1 report, which came in below expectations.
Redeye provides an update following Corline’s Q1 2025 report.
Redeye noted that BeammWave's Q1 2025 report significantly exceeded expectations, primarily due to r...
